167 related articles for article (PubMed ID: 26507190)
1. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
3. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.
Ludwig H; Bokemeyer C; Aapro M; Boccadoro M; Gascón P; Denhaerynck K; Krendyukov A; Abraham I; MacDonald K
Future Oncol; 2019 Mar; 15(8):897-907. PubMed ID: 30827127
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study).
Aapro M; Bokemeyer C; Ludwig H; Gascón P; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; MacDonald K; Abraham I
J Geriatr Oncol; 2017 Mar; 8(2):86-95. PubMed ID: 27829539
[TBL] [Abstract][Full Text] [Related]
6. Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Fruehauf S; Otremba B; Stötzer O; Rudolph C
Adv Ther; 2016 Nov; 33(11):1983-2000. PubMed ID: 27743353
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
10. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
[TBL] [Abstract][Full Text] [Related]
11. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
[TBL] [Abstract][Full Text] [Related]
12. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.
Damaj GL; Benbrahim O; Hacini M; Voronina I; Benabed K; Soumoudronga RF; Gasnereau I; Haioun C; Solal-Céligny P
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):362-369.e2. PubMed ID: 28622961
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.
Ludwig H; Gascón P; Bokemeyer C; Aapro M; Boccadoro M; Denhaerynck K; Krendyukov A; MacDonald K; Abraham I
Support Care Cancer; 2019 Jun; 27(6):2301-2312. PubMed ID: 30343410
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
15. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
[TBL] [Abstract][Full Text] [Related]
16. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
17. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
18. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg.
Fontaine C; Claes N; Graas MP; Samani KK; Vuylsteke P; Vulsteke C
Acta Clin Belg; 2021 Feb; 76(1):10-15. PubMed ID: 31399016
[No Abstract] [Full Text] [Related]
19. Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data.
Rastogi S; Shukla S; Sharma AK; Sarwat M; Srivastava P; Katiyar T; Kalaiselvan V; Singh GN
Toxicol Appl Pharmacol; 2020 May; 395():114976. PubMed ID: 32222375
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
